Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Endometrial Neoplasms 2Uterine Neoplasms 1Recurrence 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Colorectal Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1

Interventions

Fluorouracil 87Leucovorin 78Oxaliplatin 77Irinotecan 76Bevacizumab 50Cetuximab 42Capecitabine 42Panitumumab 17Folfox protocol 16Floxuridine 11Chemotherapy, Adjuvant 11regorafenib 10IFL protocol 10Nivolumab 9Drug Therapy 9trifluridine tipiracil drug combination 8Surgical Procedures, Operative 8Neoadjuvant Therapy 8sargramostim 7pembrolizumab 7XELOX 7Specimen Handling 7Biopsy 7Trastuzumab 6Radiotherapy 6Magnetic Resonance Spectroscopy 6HMPL-013 6tislelizumab 5encorafenib 5Trifluridine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Colonic Neoplasms × gedatolisib × Clear all
NCT01925274 2019-01-08

A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer

Pfizer

Phase 2 Terminated
19 enrolled 32 charts
Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡